

## Bullous pemphigoid in a psoriatic patient after adalimumab therapy: Remission with ustekinumab

A Papadopoulou, AV RoussakiSchultze and E Zafiriou

University of Thessaly, Greece



### Abstract

Bullous pemphigoid (BP) is an acquired autoimmune blistering disease affecting especially the elderly. Among drugs implicated in BP pathogenesis, anti TNF $\alpha$  agents have been reported as inducing agents. Ustekinumab is a monoclonal antibody that targets the IL-12/23 receptor and is approved for treating moderate to severe psoriasis. Coexistence of BP and psoriasis represents a therapeutic challenge. We report a 52 year old male patient with psoriasis who developed BP after treated with adalimumab. Long term remission of both cutaneous diseases was achieved after administration of ustekinumab. In our knowledge, this is the second case of completely resolution of BP and psoriasis with monoclonal IL-12/23 agent.

### Biography

A Papadopoulou is undertaking a PhD with the title “Assessing the value of community arts-based public health interventions for use in economic evaluation” under the supervision of Prof. Helen Mason (DoS) and Prof. Gianna Cassidy. Her research study is mainly focused on valuing and refining outcome measures for economic evaluations in health by using a mixed-method approach. Current research project includes the evaluation of organized street music events in New York City (Sing for Hope).



[5<sup>th</sup> International Congress on Dermatology and Trichology | July 22, 2020](#)

**Citation:** A Papadopoulou, Bullous pemphigoid in a psoriatic patient after adalimumab therapy: Remission with ustekinumab, Dermatology Congress 2020, 5th International Conference on Dermatology and Trichology, July 22, 2020, 02.